Lyell Immunopharma, Inc. (LYEL) Bundle
Understanding Lyell Immunopharma, Inc. (LYEL) Revenue Streams
Understanding Lyell Immunopharma, Inc. Revenue Streams
Lyell Immunopharma, Inc. has reported revenue primarily derived from its research collaborations and other operating income. Below is a detailed analysis of its revenue streams for 2024.
Breakdown of Primary Revenue Sources
- Revenue for Q3 2024: $34,000
- Revenue for Q3 2023: $25,000
- Revenue for the first nine months of 2024: $50,000
- Revenue for the first nine months of 2023: $117,000
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth shows a significant fluctuation:
- Q3 2024 vs. Q3 2023: Revenue increased by 36%.
- First nine months of 2024 vs. 2023: Revenue decreased by 57%.
Contribution of Different Business Segments to Overall Revenue
| Segment | Q3 2024 Revenue | Q3 2023 Revenue | Nine Months 2024 Revenue | Nine Months 2023 Revenue |
|---|---|---|---|---|
| Research Collaborations | $34,000 | $25,000 | $50,000 | $117,000 |
| Other Operating Income | Included in above | Included in above | Included in above | Included in above |
Analysis of Significant Changes in Revenue Streams
In Q3 2024, the revenue increase compared to Q3 2023 can be attributed to improved performance in research collaborations. However, the decline in total revenue for the first nine months of 2024 compared to the same period in 2023 highlights challenges in sustaining revenue growth, likely due to fewer active collaborations in the recent period.
The overall revenue performance indicates a need for strategic adjustments to enhance revenue generation, especially in a competitive biotechnology landscape.
A Deep Dive into Lyell Immunopharma, Inc. (LYEL) Profitability
A Deep Dive into Lyell Immunopharma, Inc.'s Profitability
The profitability metrics of Lyell Immunopharma, Inc. (LYEL) provide critical insights into the company's financial health and operational efficiency. Below is a detailed analysis of its gross profit, operating profit, and net profit margins, alongside trends in profitability over time.
Gross Profit, Operating Profit, and Net Profit Margins
For the three months ended September 30, 2024, the company's revenue was $34,000 with total operating expenses amounting to $50,539,000, resulting in a loss from operations of ($50,505,000). The net loss for the same period was ($44,583,000), translating to a net loss per share of ($0.17).
Trends in Profitability Over Time
Comparing the financial results for the nine months ended September 30, 2024, and 2023, the revenue decreased from $117,000 in 2023 to $50,000 in 2024. Operating expenses also saw a decline from $187,617,000 in 2023 to $157,658,000 in 2024, indicating a reduction in operational costs despite the drop in revenue. The net loss improved from ($181,702,000) in 2023 to ($151,059,000) in 2024.
Comparison of Profitability Ratios with Industry Averages
In terms of profitability ratios, Lyell's gross margin can be calculated as follows:
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $50,000 | $117,000 |
| Operating Expenses | $157,658,000 | $187,617,000 |
| Net Loss | ($151,059,000) | ($181,702,000) |
| Gross Margin (%) | 0.07% | 0.12% |
| Operating Margin (%) | (101.0%) | (155.0%) |
| Net Margin (%) | (302.1%) | (155.1%) |
These margins indicate that while the gross margin has decreased, the operational efficiency has improved as the company has managed to reduce its operating expenses significantly.
Analysis of Operational Efficiency
In terms of operational efficiency, research and development expenses were $122,935,000 for the nine months ended September 30, 2024, down from $135,950,000 in 2023, demonstrating effective cost management. General and administrative expenses also decreased from $53,816,000 to $37,519,000 over the same period, reflecting a strategic focus on reducing overhead costs.
Overall, the trends in profitability metrics for Lyell Immunopharma, Inc. suggest a company in transition, with efforts to streamline operations and manage costs in the face of declining revenues.
Debt vs. Equity: How Lyell Immunopharma, Inc. (LYEL) Finances Its Growth
Debt vs. Equity: How Lyell Immunopharma, Inc. Finances Its Growth
Debt Levels:
As of September 30, 2024, the company reported total liabilities of $88.5 million, which includes:
- Current liabilities: $33.5 million
- Non-current operating lease liabilities: $51.4 million
- Other non-current liabilities: $3.6 million
The short-term portion of lease liabilities included in accrued liabilities and other current liabilities is $7.1 million .
Debt-to-Equity Ratio:
The debt-to-equity ratio as of September 30, 2024, is calculated as follows:
- Total liabilities: $88.5 million
- Total stockholders’ equity: $530.7 million
Thus, the debt-to-equity ratio is approximately 0.17, which is significantly lower than the industry average of about 0.5 to 0.6 for biotechnology firms.
Recent Debt Issuances and Credit Ratings:
The company has not issued any new long-term debt recently. However, it has maintained a strong liquidity position with $460.7 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
Credit ratings are not explicitly provided, but the company’s financial stability and low debt levels suggest a favorable credit outlook.
Debt Financing vs. Equity Funding:
The company has primarily financed its operations through equity financing, raising approximately $1.4 billion from sales of common stock and convertible preferred stock since inception. The latest sales agreement allows for the potential issuance of up to $150 million in common stock.
This strategy reduces reliance on debt financing, allowing the company to maintain a lower debt burden and a favorable debt-to-equity ratio, which is critical in the high-risk biotechnology sector.
| Financial Metric | Amount (in millions) |
|---|---|
| Total Liabilities | $88.5 |
| Total Stockholders' Equity | $530.7 |
| Debt-to-Equity Ratio | 0.17 |
| Cash, Cash Equivalents, and Marketable Securities | $460.7 |
| Equity Raised Since Inception | $1,400.0 |
| Potential Equity Issuance | $150.0 |
By focusing on equity financing, the company effectively mitigates risks associated with high leverage, maintaining operational flexibility while pursuing its growth objectives in the biotechnology sector.
Assessing Lyell Immunopharma, Inc. (LYEL) Liquidity
Assessing Lyell Immunopharma, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current assets amounted to $460.7 million, while current liabilities were $33.5 million. The current ratio is calculated as follows:
Current Ratio = Current Assets / Current Liabilities = $460.7 million / $33.5 million = 13.74
Quick Ratio: To determine the quick ratio, we consider the current assets minus inventories. Given that there are no inventories reported, the quick ratio remains:
Quick Ratio = (Current Assets - Inventories) / Current Liabilities = $460.7 million / $33.5 million = 13.74
Analysis of Working Capital Trends
The working capital as of September 30, 2024, is:
Working Capital = Current Assets - Current Liabilities = $460.7 million - $33.5 million = $427.2 million
Comparatively, as of December 31, 2023, the working capital was:
Working Capital (Dec 31, 2023) = Current Assets - Current Liabilities = $544.8 million - $34.5 million = $510.3 million
Cash Flow Statements Overview
CASH FLOWS FROM OPERATING ACTIVITIES:
| Period | Net Loss | Stock-Based Compensation | Depreciation and Amortization | Net Cash Used |
|---|---|---|---|---|
| Nine Months Ended September 30, 2024 | ($151,059) | $25,061 | $14,605 | ($115,152) |
| Nine Months Ended September 30, 2023 | ($181,702) | $38,621 | $15,193 | ($123,059) |
CASH FLOWS FROM INVESTING ACTIVITIES:
| Period | Cash Provided |
|---|---|
| Nine Months Ended September 30, 2024 | $68,919 |
| Nine Months Ended September 30, 2023 | $284,738 |
CASH FLOWS FROM FINANCING ACTIVITIES:
| Period | Cash Provided |
|---|---|
| Nine Months Ended September 30, 2024 | $889 |
| Nine Months Ended September 30, 2023 | $984 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the total cash, cash equivalents, and marketable securities were reported at $460.7 million. The company has raised an aggregate of $1.4 billion in gross proceeds from sales of common stock and convertible preferred stock to date. Future capital requirements are anticipated to necessitate additional funding as operations expand. The company has a sales agreement in place with Cowen for an aggregate offering price of up to $150 million.
Is Lyell Immunopharma, Inc. (LYEL) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the company reported a net loss of $151.1 million for the nine months ended, compared to a net loss of $181.7 million for the same period in 2023. The basic and diluted net loss per common share was $0.59 for the nine months ended September 30, 2024.
Price-to-Earnings (P/E) Ratio
The company does not currently have positive earnings, thus the P/E ratio is not applicable. Instead, the focus is on future potential earnings as the company develops its products.
Price-to-Book (P/B) Ratio
As of September 30, 2024, the total stockholders’ equity was $530.7 million with 256.6 million shares outstanding. This results in a book value per share of approximately $2.07. If the stock price is assumed to be $1.94, the P/B ratio would be 0.94.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The company reported operating expenses of $157.7 million for the nine months ended September 30, 2024. With no EBITDA reported due to ongoing losses, the EV/EBITDA ratio is also not applicable at this time.
Stock Price Trends
Over the last 12 months, the stock price ranged from a high of $3.00 to a low of $1.50, reflecting significant volatility.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, hence the dividend yield is 0%.
Analyst Consensus on Stock Valuation
Current analyst consensus indicates a rating of Hold based on the lack of immediate profitability and ongoing research and development expenditures.
| Valuation Metric | Value |
|---|---|
| Net Loss (9 months ended Sep 30, 2024) | $151.1 million |
| Net Loss per Share (basic and diluted) | $0.59 |
| Book Value per Share | $2.07 |
| P/B Ratio | 0.94 |
| Stock Price Range (Last 12 Months) | $1.50 - $3.00 |
| Dividend Yield | 0% |
| Analyst Consensus Rating | Hold |
Key Risks Facing Lyell Immunopharma, Inc. (LYEL)
Key Risks Facing Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. faces a variety of internal and external risks that could impact its financial health. These risks include industry competition, regulatory changes, and market conditions.
Industry Competition
The biotechnology sector is highly competitive, with numerous companies developing similar therapies. As of September 30, 2024, the company reported a net loss of $151.1 million, which reflects the intense competition and the need for continuous innovation to maintain market relevance. The company has not yet commercialized any product candidates, which places it at a disadvantage compared to competitors with approved products.
Regulatory Risks
Regulatory changes can significantly affect the company’s operations. The approval process for new therapies is lengthy and complex, and any changes in regulations could delay product development. The company anticipates needing to conduct extensive clinical trials, which could be affected by regulatory scrutiny. As of September 30, 2024, the company has incurred significant operating losses, highlighting the financial pressure from ongoing regulatory compliance costs.
Market Conditions
Market conditions, including economic downturns and shifts in investor sentiment, can adversely affect the company's ability to raise capital. As of September 30, 2024, the company had $460.7 million in cash, cash equivalents, and marketable securities, which it believes will be sufficient to meet its needs into 2027. However, the company may still require additional capital in the future, particularly if market conditions worsen.
Operational Risks
Operational risks include reliance on third parties for clinical trials and manufacturing. The company has reported that it expects to incur additional losses as it conducts and expands its research and development efforts. The total amount of success payments the company may become obligated to make is currently $400.0 million, which could drain cash resources.
Financial Risks
Financially, the company has experienced significant losses. For the nine months ended September 30, 2024, the company reported a net loss of $151.1 million compared to $181.7 million for the same period in 2023. The company’s accumulated deficit as of September 30, 2024, stood at $1.15 billion, underscoring its ongoing financial challenges.
Mitigation Strategies
The company has entered into a sales agreement to potentially raise up to $150.0 million through at-the-market equity offerings, which may help mitigate some financial risks. Additionally, the company is focusing on strategic collaborations and partnerships to enhance its research and development capabilities while managing operational costs.
| Key Financial Metrics | As of September 30, 2024 | As of September 30, 2023 |
|---|---|---|
| Net Loss | $151.1 million | $181.7 million |
| Cash, Cash Equivalents, and Marketable Securities | $460.7 million | $286.5 million |
| Accumulated Deficit | $1.15 billion | $949.2 million |
| Success Payment Obligations | $400.0 million | N/A |
The risks outlined above highlight the challenging environment in which the company operates and the necessity for careful strategic planning to navigate these challenges effectively.
Future Growth Prospects for Lyell Immunopharma, Inc. (LYEL)
Future Growth Prospects for Lyell Immunopharma, Inc.
Key Growth Drivers
Lyell Immunopharma is positioned for growth through several key drivers:
- Product Innovations: The company continues to advance its pipeline with a focus on next-generation cell therapies, particularly for solid tumors.
- Market Expansions: Plans to penetrate new therapeutic areas, including autoimmune diseases, are expected to broaden their market reach.
- Acquisitions: The acquisition of ImmPACT has bolstered the company's capabilities in engineered T cell therapies, enhancing its competitive edge.
Future Revenue Growth Projections and Earnings Estimates
The revenue trajectory for Lyell Immunopharma shows potential for significant growth. For the nine months ending September 30, 2024, the revenue was reported at $50,000, a decrease from $117,000 in the same period of 2023. Analysts project a recovery as new therapies enter clinical trials and gain market approval.
Operating expenses are anticipated to stabilize, with research and development expenses reaching $122,935,000 for the nine months ending September 30, 2024, down from $135,950,000 in 2023, suggesting improved operational efficiency.
Strategic Initiatives or Partnerships
The company has engaged in strategic partnerships aimed at enhancing its research capabilities and accelerating product development. A notable partnership is with Fred Hutch, which focuses on advancing cell therapy technologies.
Additionally, the company has entered into a sales agreement with Cowen and Company to raise up to $150,000,000 through at-the-market offerings, providing financial flexibility for ongoing projects .
Competitive Advantages
Lyell Immunopharma's competitive advantages stem from its robust technology platform and strong intellectual property portfolio. The company has raised $1.4 billion in gross proceeds from sales of common stock and convertible preferred stock, allowing for substantial investment in R&D .
Moreover, the company's focus on personalized T cell therapies aligns with current trends in oncology, providing a unique position in an increasingly competitive market.
| Metric | 2024 (9 months) | 2023 (9 months) | Change |
|---|---|---|---|
| Revenue | $50,000 | $117,000 | -$67,000 |
| R&D Expenses | $122,935,000 | $135,950,000 | -13,015,000 |
| Net Loss | $151,059,000 | $181,702,000 | +$30,643,000 |
| Cash, Cash Equivalents, and Marketable Securities | $460,700,000 | N/A | N/A |
| Acquisition Cost (ImmPACT) | $30,000,000 | N/A | N/A |
As of September 30, 2024, the company holds $460.7 million in cash, cash equivalents, and marketable securities, providing a solid foundation for future growth .
Lyell Immunopharma, Inc. (LYEL) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Lyell Immunopharma, Inc. (LYEL) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Lyell Immunopharma, Inc. (LYEL)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Lyell Immunopharma, Inc. (LYEL)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.